aibioBone Biologics completes $3.0 million private placement with warrants
Tickers BBLG
A single healthcare-focused institutional investor bought the shares. The company says the financing extends its runway through Q2 2027, and warrants could add up to about $6.0 million more if exercised for cash.
Key facts
- Company
- Bone Biologics Corporation (NASDAQ: BBLG)
- News type
- Company Updates
- Primary source
- Bone Biologics press release (Form 8-K, Exhibit 99.1)
Bone Biologics Corporation (Nasdaq: BBLG) said on July 23, 2026 that it had completed a private placement in July 2026 with a single healthcare-focused institutional investor. The shares were priced at-the-market under Nasdaq rules. The company described the deal in a mid-year shareholder update that summarizes its progress through the first half of 2026. Gross proceeds were approximately $3.0 million, before deducting placement agent fees and offering expenses.
The terms
The financing also included Series F warrants and Series G warrants. The company says that if all of them were exercised on a cash basis, they would provide up to approximately $6.0 million of additional gross proceeds. The release states that no assurance can be given that any of the warrants will be exercised, or that the company will receive cash proceeds from their exercise.
The release refers to placement agent fees but does not name the placement agent. It also does not name any other bank, adviser or law firm connected with the placement.
The company intends to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes. It believes the financing extends its operating runway through Q2 2027. Chief Executive Officer Jeff Frelick said the financing provides the runway to advance the first-in-human study and to execute the regulatory and operational priorities through that date.
What the company does
Bone Biologics describes itself as a medical device company focused on bone regeneration in spinal fusion. Its platform is the recombinant human protein known as NELL-1, which the company licenses exclusively from the UCLA Technology Development Group on behalf of the UC Regents. Its lead product candidate, NB1, combines NELL-1 with demineralized bone matrix, known as DBM, which the 10-K says comes from MTF Biologics.
The 10-K also reports that FDA guidance indicates NELL-1 combined with DBM will be classified as a device and drug combination product. That classification will require an approved premarket approval application before the product can be commercialized in the United States.
The company is running a pilot clinical study of NB1 in Australia. The study is designed to enroll up to 30 adult subjects who undergo transforaminal lumbar interbody fusion to treat degenerative disc disease. According to the 10-K, the FDA's Division of Orthopedic Devices agreed on the study design in a pre-submission, to support progression to a pivotal clinical trial in the United States.
In the shareholder update, the company said it expects to complete patient enrollment in the study by year-end, and that it may provide interim updates as appropriate. In May 2026 it announced that the validated shelf life of its rhNELL-1 protein had been extended to 29 months. That milestone builds on the 24-month shelf life reached in December 2025.
Financial position
The 10-K, filed March 2, 2026, reports research and development expense of $1.1 million for 2025, compared with $2.1 million for 2024. The net loss was $3.1 million in 2025, against $4.1 million a year earlier. Cash from operations was negative $2.7 million in 2025 and negative $4.1 million in 2024.
The release does not give a cash balance for any date after the 10-K.
What the update does not show
The release is a progress report, not a results report. NB1 has no efficacy or safety data in it. The pilot study is still enrolling, with completion of enrollment targeted for year-end, so results are further out, and a pivotal U.S. trial and a premarket approval application still lie ahead. The company says its first-half steps "reduce execution risk", which is its own view.
The money is small and short. About $3.0 million gross, before fees, compares with $2.7 million of cash used in operations in 2025, and the company says it buys a runway only through Q2 2027, which it describes as removing near-term reliance on further financing. The warrants add up to about $6.0 million only if investors choose to exercise them. New shares and warrants dilute existing holders, and the release gives no price or share count.